 |
 |
 |
 |
 |
 |
|
|
ABIOMED Home > News > ABIOMED Launches New Clinical Education and Support Program Designed to Improve Recovery |
||||||||||||
 |
||||||||||||||
| ABIOMED Launches New Clinical Education and Support Program Designed to Improve Recovery | ||||||||||||||
| Program
features interactive training course, available for preview at www.abiomed.com
DANVERS, Mass. (December 09, 2004) – ABIOMED, Inc. (NASDAQ: ABMD) a manufacturer of products for circulatory care and support, today announced the launch of a new education and support program designed to promote heart recovery. The program combines clinical training, web-based education, process improvement, and field service. "By providing clinical support and education on best practices including early implantation, time on support, and reducing bleeding, we can help our hospitals improve outcomes," said Michael R. Minogue, CEO and President of ABIOMED. "Our goal is to give our customers the tools they need to help acute patients recover and go home with their own hearts." The program includes web-based learning module developed by eTrinsic that will enable clinical teams to be trained on the AB5000 and BVS 5000 using an interactive course that simulates the clinical experience. The course will also share the techniques and practices that have been shown to promote survival and recovery at ABIOMED's top centers. For instance, at the top 20% of centers in the company's installed base, the survival rate for patients implanted with ABIOMED's Ventricular Assist Devices (VADs) is greater than 50%.* The courses are accredited and healthcare providers that successfully complete the modules are eligible to receive continuing education credits. Additional clinical modules on ABIOMED's products and a general program designed to educate patients and families will be available in the near future. In addition, ABIOMED is offering its support program customers an on-site productivity and best practices consult, a reimbursement kit, and a media and marketing kit. The media and marketing kit will provide hospitals with the tools necessary to educate audiences including referring cardiologists, VAD coordinators, patients, families, and health reporters on the addition of this life-saving technology. The Best Practices consult will include an analysis of both clinical and administrative practices, and offer solutions to optimize reimbursement, improve processes and enhance patient outcomes. About ABIOMED Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced "AB'-EE-O-MED") is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. ABIOMED, which currently sells the BVS® 5000 Biventricular Support System and the AB5000™ Circulatory Support System, is the market leader in devices for the temporary support of patients with failing but potentially recoverable hearts. In September 2004, ABIOMED applied for initial FDA market approval for the AbioCor Implantable Replacement Heart to treat a defined subset of irreversible end-stage heart failure patients under a Humanitarian Device Exemption. This Release contains forward-looking statements, including statements regarding development of ABIOMED's existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events. ### Media Contact: Investor Relations Contact:
|
||||||||||||||
